You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD-1 monoclonal antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

Not yet recruiting
  • Esophagus Cancer
  • +4 more
  • Intravenous injection of P-IL-2
  • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
  • (no location specified)
Apr 24, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Solid Tumor Trial (GS-4528, Zimberelimab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Apr 21, 2023

NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

Recruiting
  • NSCLC
  • PEF
  • Anti-PD-1 monoclonal antibody
  • Guangzhou, Guangdong, China
    The first Affiliated Hospital of Guangzhou Medical University
Aug 3, 2023

Cancer of Unknown Primary Trial in Shanghai (Recombinant humanized anti-PD-1 mAb injection)

Recruiting
  • Cancer of Unknown Primary
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 18, 2022

Patients With Advanced Solid Tumors Trial in Shanghai (ICP-189)

Not yet recruiting
  • Patients With Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
May 8, 2022

Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Beijing, China
    Cancer Hospital Chinese Academy Of Medical Sciences
Mar 14, 2022

Colorectal Cancer Metastatic Trial (HLX26, HLX10)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • (no location specified)
Oct 14, 2022

Advanced Solid Tumors Trial in Beijing (GLS-010)

Active, not recruiting
  • Advanced Solid Tumors
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
Dec 1, 2021

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Suzhou (Anti-PD-1 mAb, Lenalidomide, Azacitidine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Anti-PD-1 monoclonal antibody
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 21, 2021

NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

Recruiting
  • NSCLC
  • EGFR Gene Mutation
  • neo-antigen vaccine
  • Nanjing, China
    The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

Solid Tumor, Adult Trial (HLX35, HLX10)

Not yet recruiting
  • Solid Tumor, Adult
  • (no location specified)
Jun 29, 2022

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

Completed
  • Neoplasm
  • Chuo-Ku, Japan
  • +1 more
Nov 3, 2022

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Advanced Solid Tumor Trial in Zhengzhou, Linyi (BAT4706 Injection, BAT1308 Injection)

Not yet recruiting
  • Advanced Solid Tumor
  • BAT4706 Injection
  • BAT1308 Injection
  • Zhengzhou, Henan, China
  • +2 more
Nov 14, 2023

Advanced Solid Tumors Trial in Beijing (BMS-986213)

Recruiting
  • Advanced Solid Tumors
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Advanced Solid Tumor, Solid Tumor Trial (BGB-26808, Tislelizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Solid Tumor
  • (no location specified)
Aug 7, 2023

Advanced Solid Tumors Trial in Hangzhou (QL1604 injection)

Active, not recruiting
  • Advanced Solid Tumors
  • QL1604 injection
  • Hangzhou, Zhejiang, China
    Cancer Hospital of The University of Chinese Academy of Sciences
Dec 5, 2022

Advanced Solid Tumors Trial in Shanghai (Relatlimab, Nivolumab)

Not yet recruiting
  • Advanced Solid Tumors
  • Relatlimab
  • Nivolumab
  • Shanghai, Shanghai, China
    Local Institution
Aug 10, 2022

Advanced Solid Tumor Trial (STI-7349, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Aug 3, 2023